NAMS Menopause Exam Q-Bank – Complete Certified
Menopause Practitioner Practice Questions with
Verified Answers & Explanations – Updated
2025/2026 Study Resource
INTRODUCTION
Master the North American Menopause Society (NAMS/The Menopause
Society) credentialing standards with this premium, high-yield practice
question bank. Specifically engineered for clinicians aiming to become a
Certified Menopause Practitioner (NCMP), this comprehensive study
resource features detailed, multi-paragraph case studies and
pharmacotherapeutic breakdowns. Each question is immediately paired
with its verified answer and an evidence-based clinical explanation to
ensure active active learning and perfect exam preparation. Whether you
are an advanced practice nurse, a primary care physician, or a
specialized gynecologist, this updated 2025/2026 guide serves as your
ultimate toolkit to pass the exam with absolute confidence.
Question 1
A 51-year-old woman presents with severe hot flashes and night sweats
disrupting her sleep. She has a history of intact uterus and no
contraindications to hormone therapy. Which of the following is the most
,appropriate initial FDA-approved hormone therapy regimen?
A) Transdermal estradiol patch alone
B) Oral conjugated estrogens combined with medroxyprogesterone
acetate
C) Oral estradiol alone
D) Intravaginal prasterone
Verified Answer: B
Explanation: Women with an intact uterus who require systemic
estrogen therapy for vasomotor symptoms must also receive a
progestogen (such as medroxyprogesterone acetate or micronized
progesterone) to protect against estrogen-induced endometrial
hyperplasia and neoplasia. Estrogen-alone therapy (Options A and C)
is reserved strictly for women who have undergone a hysterectomy.
Intravaginal prasterone (Option D) is a local treatment for
genitourinary syndrome of menopause (GSM) and does not treat
systemic vasomotor symptoms.
Question 2
According to the STRAW+10 (Stages of Reproductive Aging Workshop)
staging system, which biomarker changes are most characteristic of the
late menopausal transition (Stage -1)?
A) Constantly low FSH and high AMH
B) Elevated FSH (>25 IU/L) with high variability and low AMH
C) Stable, low LH and normal inhibin B
D) Fluctuating hCG and high progesterone
,Verified Answer: B
Explanation: The late menopausal transition (Stage -1) is
characterized by a marked increase in follicle-stimulating hormone
(FSH) levels, often exceeding 25 IU/L, alongside significant cycle-to-
cycle variability. Anti-Müllerian hormone (AMH) and inhibin B levels
drop dramatically during this phase as the ovarian follicle pool
depletes.
Question 3
A 48-year-old patient complains of severe dyspareunia, vaginal dryness,
and urinary urgency. Physical exam reveals pale, thin vaginal mucosa with
loss of rugae. What is the first-line, low-risk prescription therapeutic
option for this condition?
A) High-dose oral conjugated estrogens
B) Low-dose vaginal estrogen cream or tablet
C) Systemic testosterone injections
D) Oral flibanserin
Verified Answer: B
Explanation: The patient exhibits classic signs of Genitourinary
Syndrome of Menopause (GSM). First-line prescription therapy
consists of low-dose local vaginal estrogens (creams, tablets, or
rings). Because local absorption is minimal, it effectively restores
vaginal tissue health without significantly raising systemic estrogen
levels, minimizing systemic risks.
Question 4
, Which of the following non-hormonal medications is FDA-approved
specifically for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause?
A) Gabapentin
B) Venlafaxine
C) Fezolinetant
D) Clonidine
Verified Answer: C
Explanation: Fezolinetant is an FDA-approved non-hormonal
neurokinin 3 (NK3) receptor antagonist designed specifically to
treat moderate-to-severe vasomotor symptoms by acting directly
on the thermoregulatory center in the hypothalamus. While
gabapentin, venlafaxine, and clonidine are used off-label, they are
not specifically FDA-approved for this indication.
Question 5
A 53-year-old woman with a history of deep vein thrombosis (DVT) 3
years ago requests treatment for debilitating hot flashes. Which
formulation represents the safest approach if hormone therapy is
considered?
A) Oral micronized progesterone alone
B) Transdermal estradiol patch combined with oral micronized
progesterone
C) Non-hormonal therapies should be used; systemic estrogen is
contraindicated
Menopause Practitioner Practice Questions with
Verified Answers & Explanations – Updated
2025/2026 Study Resource
INTRODUCTION
Master the North American Menopause Society (NAMS/The Menopause
Society) credentialing standards with this premium, high-yield practice
question bank. Specifically engineered for clinicians aiming to become a
Certified Menopause Practitioner (NCMP), this comprehensive study
resource features detailed, multi-paragraph case studies and
pharmacotherapeutic breakdowns. Each question is immediately paired
with its verified answer and an evidence-based clinical explanation to
ensure active active learning and perfect exam preparation. Whether you
are an advanced practice nurse, a primary care physician, or a
specialized gynecologist, this updated 2025/2026 guide serves as your
ultimate toolkit to pass the exam with absolute confidence.
Question 1
A 51-year-old woman presents with severe hot flashes and night sweats
disrupting her sleep. She has a history of intact uterus and no
contraindications to hormone therapy. Which of the following is the most
,appropriate initial FDA-approved hormone therapy regimen?
A) Transdermal estradiol patch alone
B) Oral conjugated estrogens combined with medroxyprogesterone
acetate
C) Oral estradiol alone
D) Intravaginal prasterone
Verified Answer: B
Explanation: Women with an intact uterus who require systemic
estrogen therapy for vasomotor symptoms must also receive a
progestogen (such as medroxyprogesterone acetate or micronized
progesterone) to protect against estrogen-induced endometrial
hyperplasia and neoplasia. Estrogen-alone therapy (Options A and C)
is reserved strictly for women who have undergone a hysterectomy.
Intravaginal prasterone (Option D) is a local treatment for
genitourinary syndrome of menopause (GSM) and does not treat
systemic vasomotor symptoms.
Question 2
According to the STRAW+10 (Stages of Reproductive Aging Workshop)
staging system, which biomarker changes are most characteristic of the
late menopausal transition (Stage -1)?
A) Constantly low FSH and high AMH
B) Elevated FSH (>25 IU/L) with high variability and low AMH
C) Stable, low LH and normal inhibin B
D) Fluctuating hCG and high progesterone
,Verified Answer: B
Explanation: The late menopausal transition (Stage -1) is
characterized by a marked increase in follicle-stimulating hormone
(FSH) levels, often exceeding 25 IU/L, alongside significant cycle-to-
cycle variability. Anti-Müllerian hormone (AMH) and inhibin B levels
drop dramatically during this phase as the ovarian follicle pool
depletes.
Question 3
A 48-year-old patient complains of severe dyspareunia, vaginal dryness,
and urinary urgency. Physical exam reveals pale, thin vaginal mucosa with
loss of rugae. What is the first-line, low-risk prescription therapeutic
option for this condition?
A) High-dose oral conjugated estrogens
B) Low-dose vaginal estrogen cream or tablet
C) Systemic testosterone injections
D) Oral flibanserin
Verified Answer: B
Explanation: The patient exhibits classic signs of Genitourinary
Syndrome of Menopause (GSM). First-line prescription therapy
consists of low-dose local vaginal estrogens (creams, tablets, or
rings). Because local absorption is minimal, it effectively restores
vaginal tissue health without significantly raising systemic estrogen
levels, minimizing systemic risks.
Question 4
, Which of the following non-hormonal medications is FDA-approved
specifically for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause?
A) Gabapentin
B) Venlafaxine
C) Fezolinetant
D) Clonidine
Verified Answer: C
Explanation: Fezolinetant is an FDA-approved non-hormonal
neurokinin 3 (NK3) receptor antagonist designed specifically to
treat moderate-to-severe vasomotor symptoms by acting directly
on the thermoregulatory center in the hypothalamus. While
gabapentin, venlafaxine, and clonidine are used off-label, they are
not specifically FDA-approved for this indication.
Question 5
A 53-year-old woman with a history of deep vein thrombosis (DVT) 3
years ago requests treatment for debilitating hot flashes. Which
formulation represents the safest approach if hormone therapy is
considered?
A) Oral micronized progesterone alone
B) Transdermal estradiol patch combined with oral micronized
progesterone
C) Non-hormonal therapies should be used; systemic estrogen is
contraindicated
